Life Sciences Firms Lead Offensive Patent Litigation
New survey data shows life sciences companies are increasingly aggressive in protecting their intellectual property rights.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Do you believe companies should be more aggressive in pursuing patent litigation to protect their market share?
Life sciences companies are pursuing offensive patent litigation at a rate of 17%, significantly higher than the 10% rate observed in broader market sectors. Industry survey results from Miller Johnson indicate that 74% of corporate counsel were involved in patent disputes over the past 12 months.
Why it matters
Pharmaceutical companies prioritize offensive legal strategies to safeguard market share and protect high profit margins. The sector's early adoption of AI in product development has also pushed life sciences firms to the forefront of emerging legal disputes regarding AI-assisted inventions.
Life sciences companies maintain a 17% offensive patent litigation posture compared to 10% in other sectors. Additionally, 25% of healthcare respondents now identify artificial intelligence as a present issue within their current litigation.
The players
Miller Johnson
This is a law firm that conducted the industry survey regarding intellectual property litigation trends.
The details
Companies are grappling with how U.S. patent law requires a human inventor while navigating the complexities of AI-assisted development. Meanwhile, in-house counsel often manage these high-stakes disputes by spreading litigation costs over longer periods to maintain budget stability.
Timeline
74% of counsel reported patent dispute involvement over the past 12 months.
Private equity firms invested $21.33 billion in biotech across 284 deals in 2026.
Survey results were discussed with industry experts in October 2026.
Market Landscape
The aggressive posture of life sciences firms mirrors their intense investment in research, with private equity firms deploying $21.33 billion across 284 biotech deals in 2026. This trend intensifies the competitive environment as firms race to establish intellectual property dominance in a market increasingly shaped by AI.
Increased offensive litigation in the life sciences sector may eventually impact drug pricing as companies seek to recover significant legal expenses. Investors should also note that companies leading in AI integration face unique, unresolved challenges regarding the patentability of their future products.
The takeaway
Companies should prepare for future litigation by carefully documenting human involvement in all AI-assisted research and development. Developing a proactive legal strategy is essential as courts begin to clarify the boundaries between human invention and machine-led innovation.
Further reading
For more context on current industry legal trends, visit the Healthcare section.
Source note: This article includes information reported by BioXconomy.
Live Poll
Do you believe companies should be more aggressive in pursuing patent litigation to protect their market share?
